NOS2 and tauopathy: This was also demonstrated in a tauopathy model of chronic neuroinflammation, where DMF treatment reduces astrogliosis and microgliosis triggered by TAU P301L expression, decreasing the level of pro-inflammatory markers such as IL1β and inducible nitric oxide synthase (iNOS), and promoting the shift of microglia towards a ramified resting shape.